S16 Ep24: Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Highlights from the PER® CME activity "Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.Earn CME credit by completing the full accredited activity (available through March 11, 2027):https://www.gotoper.com/tb26-her2-trop2-nsclc-activityThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.